ジカウイルス治療法の世界市場:アセトアミノフェン、その他のNSAID

Technavioが発行した調査報告書(IRTNTR31491)
◆英語タイトル:Global Zika Virus Therapeutics Market 2019-2023
◆商品コード:IRTNTR31491
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年6月19日
◆ページ数:131
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア太平洋、ヨーロッパ、中東・アフリカ、北米、南米
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥312,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、ジカウイルス治療法の世界市場について調べ、ジカウイルス治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、ジカウイルス治療法の市場規模をセグメンテーション別(製品別(アセトアミノフェン、その他のNSAID))と地域別(グローバル、アジア太平洋、ヨーロッパ、中東・アフリカ、北米、南米)に分けて算出しました。
・サマリー
・レポートの範囲
・ジカウイルス治療法の市場状況
・ジカウイルス治療法の市場規模
・ジカウイルス治療法の市場予測
・ジカウイルス治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(アセトアミノフェン、その他のNSAID)
・ジカウイルス治療法の顧客状況
・主要地域別市場規模:グローバル、アジア太平洋、ヨーロッパ、中東・アフリカ、北米、南米
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Zika Virus Therapeutics Market: About this market

Technavio’s Zika virus therapeutics market analysis considers the revenues based on products such as acetaminophen and other nonsteroidal anti-inflammatory drugs (NSAIDs). Our analysis also considers the sales of Zika virus therapeutics in North America, Asia, Europe, and ROW. In 2018, the acetaminophen segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as safety and efficacy will play a significant role in the acetaminophen segment to maintain its market position. , our global Zika virus therapeutics market report looks at factors such as the availability of serology kit for qualitative diagnosis of Zika virus infection, the high incidence rate of infection, and disease burden of Zika virus infection and associated comorbidities. However, the asymptomatic nature of the infection, lack of approved Zika virus therapeutics, and stringent regulatory guidelines may hamper the growth of the Zika virus therapeutics industry over the forecast period.

Global Zika virus therapeutics market: Overview

Rising disease burden of Zika virus infection and associated comorbidities

The incidences of Zika virus infection has been increasing at a significant rate over the last few years and is gradually reaching epidemic proportions across the globe. Zika virus infection can affect both fetuses and adults in the form of various clinical manifestations such as conjunctivitis, maculopapular pruritic rashes, arthralgia, congenital glaucoma, microcephaly, and optic neuropathy. Thus, the rising disease burden of Zika virus infection and associated comorbidities will fuel the expansion of the Zika virus therapeutics market at a CAGR of over 4% during the forecast period.

Novel approach for vaccine development

The Zika virus therapeutics market is witnessing the emergence of novel approaches for vaccine development. The use of ribonucleic acid as a vaccine is one of the novel approaches that have emerged in the market. The promising results of vaccines are further encouraging research organizations to invest in the R&D of the vaccines for human models. Thus, the emergence of novel approaches for vaccine development will fuel the growth of the market during the forecast period.

For the detailed list of factors that will drive the global Zika virus therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global Zika virus therapeutics market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Zika virus therapeutics companies, that include Aurobindo Pharma Ltd., Johnson & Johnson Services Inc., Perrigo Co. Plc, Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd.

Also, the Zika virus therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: PIPELINE ANALYSIS

PART 07: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Acetaminophen – Market size and forecast 2018-2023

Other NSAIDs – Market size and forecast 2018-2023

Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

ROW – Market size and forecast 2018-2023

North America – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 12: MARKET TRENDS

Increasing efforts by government and private organizations to facilitate vaccine development

Classification of Zika virus infection as public health emergency

Novel approach for vaccine development

PART 13: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 14: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Aurobindo Pharma Ltd.

Johnson & Johnson Services Inc.

Perrigo Co. Plc

Sun Pharmaceutical Industries Ltd.

Takeda Pharmaceutical Co. Ltd.

PART 15: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

LOE

Exhibit 01: Global infectious disease treatment market

Exhibit 02: Segments of global infectious disease treatment market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Some therapeutics in clinical trials for Zika virus infection

Exhibit 18: Product – Market share 2018-2023 (%)

Exhibit 19: Comparison by product

Exhibit 20: Acetaminophen – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Acetaminophen – Year-over-year growth 2019-2023 (%)

Exhibit 22: Other NSAIDs – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Other NSAIDs – Year-over-year growth 2019-2023 (%)

Exhibit 24: Market opportunity by product

Exhibit 25: Customer landscape

Exhibit 26: Market share by geography 2018-2023 (%)

Exhibit 27: Geographic comparison

Exhibit 28: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 29: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 30: Top 3 countries in ROW

Exhibit 31: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: North America – Year-over-year growth 2019-2023 (%)

Exhibit 33: Top 3 countries in North America

Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 36: Top 3 countries in Asia

Exhibit 37: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 38: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 39: Top 3 countries in Europe

Exhibit 40: Key leading countries

Exhibit 41: Market opportunity

Exhibit 42: Impact of drivers and challenges

Exhibit 43: Vendor landscape

Exhibit 44: Landscape disruption

Exhibit 45: Vendors covered

Exhibit 46: Vendor classification

Exhibit 47: Market positioning of vendors

Exhibit 48: Aurobindo Pharma Ltd. – Vendor overview

Exhibit 49: Aurobindo Pharma Ltd. – Business segments

Exhibit 50: Aurobindo Pharma Ltd. – Organizational developments

Exhibit 51: Aurobindo Pharma Ltd. – Geographic focus

Exhibit 52: Aurobindo Pharma Ltd. – Key offerings

Exhibit 53: Aurobindo Pharma Ltd. – Key customers

Exhibit 54: Johnson & Johnson Services, Inc. – Vendor overview

Exhibit 55: Johnson & Johnson Services, Inc. – Business segments

Exhibit 56: Johnson & Johnson Services, Inc. – Organizational developments

Exhibit 57: Johnson & Johnson Services, Inc. – Geographic focus

Exhibit 58: Johnson & Johnson Services, Inc. – Segment focus

Exhibit 59: Johnson & Johnson Services, Inc. – Key offerings

Exhibit 60: Johnson & Johnson Services, Inc. – Key customers

Exhibit 61: Perrigo Co. Plc – Vendor overview

Exhibit 62: Perrigo Co. Plc – Business segments

Exhibit 63: Perrigo Co. Plc – Organizational developments

Exhibit 64: Perrigo Co. Plc – Geographic focus

Exhibit 65: Perrigo Co. Plc – Segment focus

Exhibit 66: Perrigo Co. Plc – Key offerings

Exhibit 67: Perrigo Co. Plc – Key customers

Exhibit 68: Sun Pharmaceutical Industries Ltd. – Vendor overview

Exhibit 69: Sun Pharmaceutical Industries Ltd. – Business segments

Exhibit 70: Sun Pharmaceutical Industries Ltd. – Organizational developments

Exhibit 71: Sun Pharmaceutical Industries Ltd. – Geographic focus

Exhibit 72: Sun Pharmaceutical Industries Ltd. – Segment focus

Exhibit 73: Sun Pharmaceutical Industries Ltd. – Key offerings

Exhibit 74: Sun Pharmaceutical Industries Ltd. – Key customers

Exhibit 75: Takeda Pharmaceutical Co. Ltd. – Vendor overview

Exhibit 76: Takeda Pharmaceutical Co. Ltd. – Business segments

Exhibit 77: Takeda Pharmaceutical Co. Ltd. – Organizational developments

Exhibit 78: Takeda Pharmaceutical Co. Ltd. – Geographic focus

Exhibit 79: Takeda Pharmaceutical Co. Ltd. – Key offerings

Exhibit 80: Takeda Pharmaceutical Co. Ltd. – Key customers

Exhibit 81: Validation techniques employed for market sizing

Exhibit 82: Definition of market positioning of vendors



【掲載企業】

Aurobindo Pharma Ltd.、Johnson & Johnson Services Inc.、Perrigo Co. Plc、Sun Pharmaceutical Industries Ltd.、Takeda Pharmaceutical Co. Ltd.

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ジカウイルス治療法の世界市場:アセトアミノフェン、その他のNSAID(Global Zika Virus Therapeutics Market 2019-2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆